Anti-Ro/SSA antibodies predicted which patients were at most risk for ILD but not ILD progression or overall disease progression and death.
VIENNA — Anti-Ro/SSA antibodies may help predict which patients with systemic sclerosis are at a greater risk for interstitial lung disease and may serve as a biomarker to guide screening, according to an analysis of data from a large Europe an cohort.
"A total of 15% of all patients in the SSc cohort presented with anti-Ro/SSA antibodies, and this subgroup presented with distinct clinical features: Importantly, higher prevalence of ILD and lower DLCO% in patients with established ILD," reported Burja, adding that,"However, these anti-Ro/SSA antibodies do not predict ILD progression, death, or overall disease progression."
Ospelt, who is a professor of experimental rheumatology at University Hospital Zürich and was not involved in the study, noted that"It might also be the case that we could adapt this concept and use these antibodies in other rheumatic diseases, too, not just systemic sclerosis, to predict lung involvement.
Crest Syndrome Ana Positive Antinuclear Antibody Positive Lung Interstitial Lung Disease Lung Fibrosis Pulmonary Fibrosis Systemic Sclerosis Diffuse Scleroderma Europe European Biomarker Biological Marker Multi-Biomarker Disease Activity MBDA Multibiomarker Disease Activity Hospitals Idiopathic Pulmonary Fibrosis IPF Idiopathic Pulmonary Fibrosis (IPF)
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Educational Intervention Curbs Unnecessary Inhaler UseElectronic reminder prompted clinicians to counsel ILD patients on deprescribing inhalers.
Read more »
Cancer-fighting antibodies inject chemo directly into tumor cells, upping effectivenessBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Novel vaccine concept generates immune responses that could produce multiple types of HIV broadly neutralizing antibodiesUsing a combination of cutting-edge immunologic technologies, researchers have successfully stimulated animals' immune systems to induce rare precursor B cells of a class of HIV broadly neutralizing antibodies (bNAbs). The findings are an encouraging, incremental step in developing a preventive HIV vaccine.
Read more »
Antibodies may aid effort to fight influenza BResearchers have isolated human monoclonal antibodies against influenza B, a significant public health threat that disproportionately affects children, the elderly and other immunocompromised individuals.
Read more »
In a 1st, HIV vaccine triggers rare and elusive antibodies in human patientsNicoletta Lanese is the health channel editor at Live Science and was previously a news editor and staff writer at the site. She holds a graduate certificate in science communication from UC Santa Cruz and degrees in neuroscience and dance from the University of Florida.
Read more »
Experimental HIV Vaccine Successfully Triggers Potent Antibodies in HumansThe Best in Science News and Amazing Breakthroughs
Read more »